Preclinical development of a B7-H3-targeting ADC with a novel DNA topoisomerase I inhibitor for solid tumors

被引：0
|
作者：
Li, Chenggang
Yao, Jun
Qu, Chen
Li, Bing
Zhang, Yu
Shi, Rong
Qiu, Yang
Hua, Haiqing
机构：
来源：
CANCER RESEARCH | 2023年 / 83卷 / 07期
关键词：
D O I：
10.1158/1538-7445.AM2023-2967
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
2967
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Preclinical development of YL202, a novel HER3-targeting antibody-drug conjugate (ADC) with novel DNA topoisomerase I inhibitor for treatment of solid tumors
    Xu, Jian
    Zong, Qing
    Zhu, Liang
    Liu, Qigang
    Stann, Sasha
    Cai, Jiaqiang
    CANCER RESEARCH, 2023, 83 (07)
  • [2] Preclinical development of a next generation antibody drug conjugate (ADC) targeting B7-H3 for treatment of solid tumors
    Xu, Jian
    Zong, Qing
    Wang, Wei
    Liu, Qigang
    Stann, Sasha
    Cai, Jiaqiang
    CANCER RESEARCH, 2023, 83 (07)
  • [3] DS-7300a, a novel B7-H3-targeting antibody-drug conjugate with a novel DNA topoisomerase I inhibitor DXd, exhibits potent anti-tumor effects in nonclinical models
    Yamato, M.
    Hasegawa, J.
    Hattori, C.
    Maejima, T.
    Shibutani, T.
    Deguchi, T.
    Izumi, N.
    Watanabe, A.
    Nishiya, Y.
    Nakada, T.
    Abe, Y.
    Agatsuma, T.
    EUROPEAN JOURNAL OF CANCER, 2020, 138 : S14 - S15
  • [4] Preclinical development of YL205, a novel NaPi2b-targeting antibody-drug conjugate (ADC) with novel topoisomerase I inhibitor-based linker- payload for treatment of solid tumors
    Xiao, Liang
    Lian, Wei
    Liu, Qigang
    Zong, Qing
    Song, Shuai
    Stann, Sasha
    Cai, Jiaqiang
    Xue, Tongtong
    CANCER RESEARCH, 2024, 84 (06)
  • [5] DB-1314, a novel DLL3-targeting ADC with DNA topoisomerase I inhibitor, exhibits promising therapeutic efficacy and safety profile in preclinical
    Lin, S.
    Yao, J.
    Yang, J.
    Shi, R.
    Qiu, Y.
    Hua, H.
    EUROPEAN JOURNAL OF CANCER, 2024, 211 : S71 - S72
  • [6] DB-1419, a first-in-class bispecific ADC targeting B7-H3 and PD-L1 with a DNA topoisomerase I inhibitor, exhibits promising efficacy and safety in preclinical models
    Li, C.
    Yao, J.
    Yang, J.
    Li, Z.
    Shi, R.
    Qiu, Y.
    Hua, H.
    EUROPEAN JOURNAL OF CANCER, 2024, 211 : S72 - S72
  • [7] U3-1402a, a novel HER3-targeting ADC with a novel DNA topoisomerase I inhibitor, demonstrates a potent antitumor efficacy
    Ueno, Suguru
    Hirotani, Kenji
    Abraham, Reimar
    Blum, Sabine
    Frankenberger, Birgit
    Redondo-Muller, Mauricio
    Bange, Johannes
    Ogitani, Yusuke
    Zembutsu, Akiko
    Morita, Koji
    Nakada, Takashi
    Majima, Shuji
    Abe, Yuki
    Agatsuma, Toshinori
    CANCER RESEARCH, 2017, 77
  • [8] Preclinical characterization of IPH45, a novel topoisomerase I inhibitor ADC targeting Nectin-4 for the treatment of Nectin-4 expressing tumors
    Remark, Romain
    Bonnafous, Cecile
    Chiossone, Laura
    Soulas, Caroline
    Perrier, Cyril
    Habif, Guillaume
    Bokobza, Sivan
    Maguer, Aurelie
    Courtois, Rachel
    Lopez, Julie
    Fenaux, Gregory
    Benac, Olivier
    Carrette, Barbara
    Letay-Drouet, Robin
    Bonifay, Raja
    Augier, Severine
    Simon, Lea
    Rossi, Benjamin
    Morel, Ariane
    Represa, Agnes
    Beltraminelli, Nicola
    Morel, Yannis
    Paturel, Carine
    Vivier, Eric
    CANCER RESEARCH, 2024, 84 (06)
  • [9] Results of a phase 1/2 study of MHB088C: A novel B7H3 antibody-drug conjugate (ADC) incorporating a potent DNA topoisomerase I inhibitor in recurrent or metastatic solid tumors.
    Shen, Lin
    Zhou, Caicun
    Meng, Xue
    Sun, Yuping
    Ji, Yinghua
    Yang, Haihua
    Ning, Fangling
    Han, Liang
    Jiang, Ou
    Sun, Meili
    Wen, Qing
    Yu, Xinmin
    Jia, Yuming
    Huang, Hai
    Zhao, Yanqiu
    Zhang, Zhiye
    Tian, Chuntao
    Zhang, Zhen
    Shi, Junwei
    Cao, Guoqing
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [10] Targeting B7-H3 in solid tumors: Development and evaluation of novel CAR-T Cell therapy
    Li, Ning
    Zhang, Chunhua
    Li, Xiaoyu
    Liu, Shufen
    Xu, Youhua
    Yang, Xifei
    IMMUNOBIOLOGY, 2025, 230 (03)
12345